No Data
No Data
Atara Biotherapeutics Is Maintained at Buy by Canaccord Genuity
Atara Biotherapeutics Analyst Ratings
CCORF Maintains Atara Biotherapeutics(ATRA.US) With Buy Rating, Cuts Target Price to $17
Atara Biotherapeutics Price Target Lowered to $17 From $21 at Canaccord
Express News | Atara Biotherapeutics Inc : Canaccord Genuity Cuts Target Price to $17 From $21
12 Health Care Stocks Moving In Thursday's Pre-Market Session
No Data
J JR : It remains a buy at a target price of 17. Could go down but definitely buy
72779455 OP J JR : if it reaches 5 I'll buy but not right now, I'm looking for short term investment